|
|
The company is an innovative technology service company with high efficiency, green, economic and safe asymmetric technology of high pressure hydrogenation as the core. The research technology can be widely used in the synthesis of pharmaceutical chemical raw materials and intermediates, as well as the production of chiral chemical products in the fields of fine chemical industry and large chemical industry. At present, the company mainly focuses on the synthesis of small molecule generic drugs (scientific name drugs) and related APIs and intermediates in innovative drugs.
Industry policy impact In recent years, with the development of the state and the pharmaceutical industry, the state has issued a series of policies, including new environmental protection law, drug consistency evaluation, and quantity purchase. The industry has gradually developed to be compliant and standardized. Enterprises are facing multiple pressures, including pressure and resistance from self standardization, environmental protection, cost and intellectual property rights. Among them, standardization, such as relevant production license, safety assessment, environmental impact assessment and regulatory requirements of the pharmaceutical industry, such as China's accession to the ICH global code of practice, GMP of production management that is required to comply with pharmaceutical regulations, such as domestic registration conformity evaluation requirements, etc; The environmental pressure faced by enterprises is well known; What is more urgent is the centralized procurement policy in recent years, which has further greatly increased the competition, also caused great pressure on the production cost of enterprises, and gradually eliminated some technologically backward enterprises. Under this trend, the transformation and upgrading of China's pharmaceutical industry is promoted. However, the core issue of industrial transformation and upgrading is technology. Innovative and leading technologies with high efficiency, economy, green and independent intellectual property rights are becoming more and more important.
Industry development prospects Even though the requirements of the industry are getting higher and higher, the world and Chinese api markets are still growing rapidly. In 2019, the global API industry will reach 167.9 billion US dollars, and in 2020, its scale will rise to 175.7 billion US dollars (about 1.2 trillion). Among them, China has become the world's largest producer and exporter of APIs, providing about 30% of the world's API production capacity. In 2017, the output of China's chemical raw materials was 3.478 million tons, a year-on-year increase of 5.7%, the largest in recent years, and the sales revenue of chemical raw materials industry was 499.1 billion yuan; In 2019, due to the adjustment of industrial structure, China's API output will be 2.621 million tons, a year-on-year decrease of 7.16%, and the sales revenue of chemical API industry will be 380.4 billion yuan. Although there is a downward trend in recent years, with the end of industrial structure optimization, the alleviation of the contradiction between supply and demand, and the reduction of pollution emissions, it will promote the sound development of API industry and further return to the growth trend. There is still a large space for development and business opportunities in the future.
|
